Headquartered in Fort Worth, TX Fiscal year ends December NASDAQ: OMCL omnicell.com
Omnicell is a healthcare technology company focused on autonomous medication management across the patient care journey. It sells connected devices and software licenses (product revenues), including automated medication dispensing and packaging systems; its next-generation Titan XT platform is paired with OmniSphere, a cloud-native software platform. It also generates service revenues from technical services (maintenance and support) and from SaaS and Expert Services, which include the EnlivenHealth retail pharmacy software business. Customers include hospitals and health systems, institutional, retail and specialty pharmacies, and group purchasing organizations. The company increasingly sells products and services on a subscription basis and tracks annual recurring revenue (guided at $660–$670 million for 2026). Its offerings use AI-enabled tools, enterprise intelligence and scalable automation to improve efficiency, safety, financial performance and workforce productivity in medication workflows. Omnicell recently restructured operations, including exiting its Beijing, China office. Updated
Margin is doing the work: service gross margin widened to 46.7% from 40.4% a year ago, carrying a sixth straight quarter of profit beating expectations even as revenue slipped 0.9%. Omnicell raised full-year EPS guidance to $2.48 to $2.56, though fourth-quarter revenue guidance of $295 million to $301 million points to a sequential step-down.
Omnicell is a healthcare technology company focused on autonomous medication management across the patient care journey.
The Wall Street consensus 12-month price target for OMCL is $57.43.